Nonmyeloablative Stem Cell Transplant for High-Risk Sickle Cell Disease and Beta-Thalassemia

Phase 2, open-label trial of pentostatin and cyclophosphamide in sickle cell disease (SCD) and beta thalassemia (3 arms), sponsored by National Heart, Lung, and Blood Institute. Primary endpoints: Number of Patients Who Have Sustained Donor Type Hemoglobin at One Year Post Transplant at 1 year and Number of Participants With Donor Red Cells at 2 Years Post Stem Cell Transplant. Started Apr 2014; status: active, not recruiting.